| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | OI4; EDSCV; EDSARTH2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human COL1A2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于COL1A2抗体的3篇参考文献示例(注：文献信息为示例性概括，非真实存在)：
---
1. **文献名称**：*COL1A2 Mutations and Antibody Detection in Osteogenesis Imperfecta*
**作者**：Mäkitie O, et al.
**摘要**：研究分析了COL1A2基因突变导致的成骨不全症患者，利用特异性抗体检测突变胶原蛋白的表达水平，揭示突变如何影响I型胶原的结构与功能。
2. **文献名称**：*Autoantibodies to COL1A2 in Systemic Sclerosis Pathogenesis*
**作者**：Tanjore H, et al.
**摘要**：探讨硬皮病患者血清中抗COL1A2抗体的存在及其与纤维化的关联，提出此类抗体可能通过激活成纤维细胞加剧细胞外基质沉积。
3. **文献名称**：*COL1A2 as a Stromal Biomarker in Pancreatic Cancer*
**作者**：Berchtold S, et al.
**摘要**：通过免疫组化(使用COL1A2抗体)分析胰腺癌肿瘤微环境，发现COL1A2高表达与患者预后不良相关，提示其作为潜在治疗靶点。
---
**注意**：以上为基于领域常见研究的模拟摘要，实际文献需通过学术数据库(如PubMed)检索确认。如需真实文献，建议使用关键词“COL1A2 antibody”或“COL1A2 autoantibody”进行查询。
The COL1A2 antibody targets the alpha-2 chain of type I collagen, a major structural protein in connective tissues such as skin, bone, tendons, and organs. Type I collagen, a heterotrimer composed of two α1 chains (COL1A1) and one α2 chain (COL1A2), is critical for tissue integrity and mechanical strength. COL1A2 plays a key role in collagen fibril assembly and stability, contributing to extracellular matrix (ECM) organization. Mutations in COL1A2 are linked to osteogenesis imperfecta (brittle bone disease), Ehlers-Danlos syndrome, and idiopathic pulmonary fibrosis, highlighting its biomedical significance.
COL1A2 antibodies are essential tools in research and diagnostics. They enable detection of COL1A2 expression in tissue samples, aiding studies on collagen biosynthesis, ECM remodeling, and fibrotic disorders. In clinical settings, these antibodies help identify genetic collagenopathies by analyzing protein expression patterns. Additionally, they are used to investigate tumor microenvironments, as collagen dysregulation is associated with cancer progression and metastasis. Monoclonal antibodies specific to COL1A2 are often developed for precision in immunohistochemistry, Western blotting, or ELISA, while polyclonal versions may capture broader epitopes. Recent therapeutic research explores targeting COL1A2 to modulate fibrosis or enhance tissue regeneration, though challenges remain in specificity and off-target effects. Overall, COL1A2 antibodies bridge molecular insights with clinical applications in connective tissue diseases.
×
